Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Broad Institute Rare Disease Group, |
RCV001004880 | SCV001164364 | uncertain significance | Coenzyme Q10 deficiency, primary, 1 | 2023-05-02 | criteria provided, single submitter | curation | The heterozygous c.403+4A>T variant in COQ2 was identified by our study, in the compound heterozygous state, along with a variant of uncertain significance (ClinVar Variation ID: 1439), in one individual with steroid-resistant nephrotic syndrome. Trio exome analysis revealed that this variant was in trans with a variant of uncertain significance (ClinVar Variation ID: 1439). The c.403+4A>T variant in COQ2 has not been previously reported in individuals with primary coenzyme Q10 deficiency 1 but has been identified in 0.001% (1/69650) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs907149421). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID: 813911) and has been interpreted as a variant of uncertain significance by the Broad Institute Rare Disease Group. This variant is located in the 5' splice region. Computational tools do suggest an impact to splicing. However, this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the c.403+4A>T variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015). |